A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers
Authors:
- 23 January 2002
- journal article
- review article
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 17 (1) , 1-13
Abstract
Amisulpride binds selectively to dopamine D2 and D3 receptors in the limbic system. Low doses of amisulpride preferentially block presynaptic D2/D3‐dopamine autoreceptors, thereby enhancing dopaminergic transmission, whereas higher doses block postsynaptic receptors, thus inhibiting dopaminergic hyperactivity. Amisulpride is clinically effective on the negative symptoms of acute schizophrenia exacerbations at low dosages (50–300 mg/day), and also on the positive symptoms of the disease at high dosages (400–800 mg/day). Nineteen clinical studies involving 358 volunteers have investigated the pharmacokinetics, pharmacodynamics and tolerability of amisulpride. Amisulpride shows linear pharmacokinetics, a bioavailability of 48%, low protein binding (17%) and an elimination half‐life of ∼12 h. It is predominantly eliminated in the urine as the parent compound. It exhibits no significant detrimental effects in psychometric or memory tests up to the dose of 400 mg/day, inducing only mild impairment at high doses, whereas EEG data suggest an alertness‐enhancing effect at low doses (≤ 50 mg). Moreover, amisulpride does not potentiate the depressant effects on the central nervous system of alcohol and lorazepam. This tolerability profile is clearly better than that of haloperidol 4 mg/day and is consistent with a weak blocking effect on striatal D2 receptors. In summary, studies in humans have shown that amisulpride is free of behavioural toxicity at doses exerting clear antipsychotic efficacy and confirm that its CNS effects may vary with the dose administered. Copyright © 2002 John Wiley & Sons, Ltd.Keywords
This publication has 26 references indexed in Scilit:
- Guidelines for the Use of Antipsychotic Drug Studies in Healthy VolunteersJournal of Psychopharmacology, 1997
- AmisulprideCNS Drugs, 1996
- Antipsychotic Drug-Induced DysphoriaThe British Journal of Psychiatry, 1995
- Remoxipride versus haloperidol in healthy volunteersInternational Clinical Psychopharmacology, 1995
- Psychomotor impairment and cognitive disturbances induced by neurolepticsActa Psychiatrica Scandinavica, 1994
- A comparison of the psychometric effects of remoxipride with those of haloperidol, thioridazine, and lorazepam in healthy volunteersHuman Psychopharmacology: Clinical and Experimental, 1994
- Clinical, EEG Mapping and Psychometric Studies in Negative Schizophrenia: Comparative Trials with Amisulpride and FluphenazineNeuropsychobiology, 1994
- Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptorEuropean Journal of Pharmacology: Molecular Pharmacology, 1992
- The effects of neuroleptics on neuropsychological test results of schizophrenicsArchives of Clinical Neuropsychology, 1988
- The effects of neuroleptics on neuropsychological test results of schizophrenicsArchives of Clinical Neuropsychology, 1988